BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 16289716)

  • 1. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
    Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
    Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities.
    Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C
    Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
    Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional hyperthermic perfusion with cisplatin following surgery for malignant melanoma of the extremities.
    Papa MZ; Klein E; Karni T; Koller M; Davidson B; Azizi E; Ben-Ari G
    Am J Surg; 1996 Apr; 171(4):416-20. PubMed ID: 8604833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
    Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
    Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
    Pace M; Gattai R; Mascitelli EM; Millanta L
    J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
    In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.